| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24020 |
| Drug | Sparsentan |
| Brand | Filspari® |
| Indication | For the treatment of adults with primary immunoglobulin A (IgA) nephropathy with a urine protein excretion >1.0 g/day (or urine protein-to-creatine ratio ≥0.75 g/g). |
| Assessment Process | |
| Rapid review commissioned | 30/05/2024 |
| Rapid review completed | 26/06/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of sparsentan compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/07/2024 |
| Pre-submission consultation with Applicant | 01/10/2024 |
| Full submission received from Applicant | 12/12/2024 |
| Preliminary review sent to Applicant | 18/09/2025 |
| NCPE assessment re-commenced | 17/10/2025 |
| Follow-up to preliminary review sent to Applicant | 23/10/2025 |
| NCPE assessment re-commenced | 03/11/2025 |
| Factual accuracy sent to Applicant | 17/11/2025 |
| NCPE assessment re-commenced | 24/11/2025 |
| NCPE assessment completed | 26/11/2025 |
| NCPE assessment outcome | The NCPE recommends that sparsentan not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.